Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

The product most readily identified with the company will soon hit pharmacy shelves in Australia.

Why Amarin Stock Was a Winner Today

-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 --

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference.

Amarin to Present at Jefferies London Healthcare Conference

-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients --

Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and the restructuring initiatives in the third quarter. The stock witnesses a decline on Oct 27.

Amarin (AMRN) Q3 Earnings Beat, Sales Hurt by Vascepa Generics

Amarin Corporation plc (NASDAQ:AMRN ) Q3 2022 Results Earnings Conference Call October 27, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Corporate Affairs and Investor Relations Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Georgi Yordanov - Cowen and Company Roanna Ruiz - SVB Leerink Carvey Leung - Cantor Fitzgerald Daniel Wolle - J.P. Morgan Paul Choi - Goldman Sachs Operator Welcome to Amarin Corporation's Conference Call to Discuss its Third Quarter 2022 Financial Results and Operational Update.

Amarin Corporation plc (AMRN) Q3 2022 Results - Earnings Call Transcript

-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned –

Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update

New Independent Directors Bring Significant International Experience in Healthcare and Finance

Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's third quarter 2022 financial results on Thursday, October 27th, 2022 at 8:00 a.m. ET.

Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022

On Tuesday, Sarissa Capital Management, an activist investment firm focusing on the pharmaceutical sector, put pressure on Amarin (US:AMRN) to hold a special meeting to straighten out its board issues and halt a slide that's devoured two thirds of its value this year.

Activist Sarissa Demands Special Meeting at Amarin to Hold Board Vote

-- Highlights Active Board Refreshment Process -- -- Amarin Has Engaged Proactively and Frequently with Sarissa --

Amarin Board of Directors Issues Statement in Response to Sarissa

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement regarding its ongoing discussions with Amarin Corporation plc (NASDAQ: AMRN) regarding board representation: Amarin's board seems to be trying to outdo the misguided leadership of the Roman Emperor Nero who played his lyre while Rome was engulfed in flames. Their “imperial” attitude and inaction is the problem. We, along with all shareholders, must try to fix the company. This year al

Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members

Amarin Corporation Plc (NASDAQ:AMRN ) H.C. Wainwright Global Investment Conference September 12, 2022 9:00 AM ET Company Participants Karim Mikhail - President, CEO & Director Thomas Reilly - CFO & SVP Conference Call Participants Andrew Fein - H.C.

Amarin Corporation Plc (AMRN) H.C. Wainwright Global Investment Conference Call Transcript

Editas Medicine

Sorrento Therapeutics Inc

The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.

3 Biotech Stocks Gaining Momentum

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

Amarin to Present at H.C. Wainwright's 24th Annual Global Investment Conference

-- Data Show VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively Relative to Placebo in a Post Hoc Analysis -- - - Data Presented as an Oral Abstract at European Society of Cardiology (ESC) Congress 2022 in Barcelona and Published in EHJ Cardiovascular Pharmacotherapy --

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced Cardiovascular Events in Patients Who Are Current or Former Smokers

Investors weren't happy with the company's decision to cease operations in a large country.

Why Amarin Stock Was Plunging This Week

-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses -- -- Data Presented During Late-Breaking Science Session at European Society of Cardiology (ESC) Congress 2022 in Barcelona --

New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes

Canopy Growth

Carvana

GrowGeneration Corp

Shopify

Scotts Miracle-Gro

Zoom Video

It's probably high time to look at your portfolio and see which growth stocks to sell. It has been a disappointing year on Wall Street, to say the least.

7 F-Rated Growth Stocks to Sell Before Q4

Ocugen, Inc.

This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.

Are Ocugen or Amarin Good Penny Stocks to Buy?

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded research on the effects of VASCEPA®/VAZKEPA (icosapent ethyl) in specific patient subgroups at increased risk of a cardiovascular (CV) event from the landmark REDUCE-IT® cardiovascular outcomes trial have been accepted for presentation at the European Society of Cardiology (ESC) Congress, both online and onsite in Barcelona, August 26-29, 2022.

Latest Research Evaluating VASCEPA®/VAZKEPA (icosapent ethyl) and Subgroups from the REDUCE-IT® Landmark Outcomes Trial to be Presented at the European Society of Cardiology (ESC) Congress

Amarin has seen sales of its lone drug, Vascepa, plummet against generic competition. Famed activist investor Alex Denner has recently taken a sizeable stake in the company.

For Amarin, Something Wishful This Way Comes

Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.

Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics

Amarin recently announced its earnings for Q2'22 with mixed results. Here we'll examine the pros and cons of having this penny stock in your portfolio.

Does Amarin Deserve a Spot in Your Portfolio after Earnings?

Although the company notched a revenue beat for its latest quarter, the bottom-line result fell short.

News for Amarin Corporation Plc Stock (AMRN)